Financial and geographic disparities contributing to elevated risk for heart disease are explored.
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD, CCNS, CCRN, CHFN, NE-BC, FAHA, FCCM, FHFSA, FAAN; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. The panel discusses socioeconomic factors impacting heart failure risk. Wright highlights social determinants like economic and income insecurity, food insecurity, transportation challenges, education levels, lived experiences, and psychosocial stress. Wright also highlights Individuals with lower incomes have higher cardiovascular disease risk due to increased stress hormones like catecholamines and cortisol. A person’s zip code might better predict their health than genetics.
Albert expands on the patient impact, explaining how limited income can reduce access to medications, transportation, and proper nutrition. Patients may live in food deserts without access to healthy options. Many are on fixed incomes and Medicare or Medicaid and cannot easily afford new treatments. Readmissions also financially penalize hospitals, influencing their care approaches to reduce overall readmission rates. The scope of heart failure is expanding, affecting more patients nationwide. In summary, this multifactorial disease has significant individual and societal impacts that require urgent attention.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More